Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,995 matching trials from the live ClinicalTrials.gov search.
Conditions
Agitation
Interventions
12 cm2 - 2 Active DMTS Patches, 6 cm2 - 1 Active and 1 Placebo DMTS Patches, Placebo - 2 Placebo DMTS Patches
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Chino, California • Daytona Beach, Florida • Delray Beach, Florida + 6 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's

NCT00980785
Conditions
Alzheimer's Disease, Hypertension
Interventions
Ramipril, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Conditions
Alzheimer's Disease
Interventions
Folate, Vitamin B6, Vitamin B12
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sun City, Arizona + 29 more
Conditions
Nonverbal Communication, Critical Illness
Interventions
Aim 1 - VidaTalk - post-extubation, Aim 2 - VidaTalk - intubated, Aim 3 - VidaTalk tablet app, Aim 3 - attention-control with non-VidaTalk tablet
Other · Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 99 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 3 Interventional Results available

Valproate in Dementia (VALID)

NCT00071721
Conditions
Alzheimer Disease
Interventions
Valproate, Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
46
States / cities
Sun City, Arizona • Tucson, Arizona • Irvine, California + 38 more
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Goal Setting to Promote Physical Activity Adherence in Midlife Adults

NCT05980052
Conditions
Physical Activity, Exercise
Interventions
Physical Activity
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
45 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
North Coast Medical Activadose II
Device
Lead sponsor
The Mind Research Network
Other
Eligibility
50 Years to 90 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Completed Phase 2 Interventional Results available

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404
Conditions
Mild Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Accepts healthy volunteers

Video-Based Coping Skills Training for Caregivers

NCT00396825
Conditions
Caregivers
Interventions
Video-based coping skills training with telephone coaching
Behavioral
Lead sponsor
Williams LifeSkills
Industry
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions
NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2)
Drug
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
19 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Alzheimer's Disease, Dementia
Interventions
Lifezig
Behavioral
Lead sponsor
Photozig, Inc.
Industry
Eligibility
21 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Moffett Field, California
Conditions
Alzheimer Disease, Dementia, Alzheimer Type
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
21
States / cities
Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
Conditions
Alzheimer's Disease
Interventions
AL002
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Boca Raton, Florida + 12 more
Conditions
Postoperative Cognitive Decline, Postoperative Delirium
Interventions
Daridorexant 50 mg, Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Conditions
Dementia, Alzheimer Disease
Interventions
PET/MRI
Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
21 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Alzheimer's Disease
Interventions
TPI-287 2 mg/m2, TPI-287 6.3 mg/m2, TPI-287 20 mg/m2, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of COR388

NCT03418688
Conditions
Alzheimer Disease
Interventions
COR388, Placebo
Drug
Lead sponsor
Cortexyme Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
San Diego, California • Orlando, Florida • Cincinnati, Ohio
Conditions
Alzheimer's Disease, Dementia, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years and older
Enrollment
6,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Alzheimer Dementia (AD)
Interventions
Intermittent deep brain stimulation of the nucleus basalis of Meynert
Device
Lead sponsor
Augusta University
Other
Eligibility
65 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Augusta, Georgia
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
Interventions
PrecivityAD2(TM) blood test
Other
Lead sponsor
C2N Diagnostics
Industry
Eligibility
55 Years and older
Enrollment
400 participants
Timeline
2023 – 2025
U.S. locations
9
States / cities
San Francisco, California • Santa Monica, California • Park Ridge, Illinois + 6 more
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Learning Amyloid and Tau Results

NCT07222930
Conditions
Alzheimer Disease
Interventions
Disclose amyloid, tau results, Follow-up Assessments
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
45 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Assess Fibrin in Brains With AD/ADRD

NCT05336695
Conditions
Alzheimer Disease, Dementia of Alzheimer Type
Interventions
PET/MR Imaging, 64Cu-FBP8
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts